Senti Biosciences Holdings, Inc.
SNTINasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $22,000 | $0 | $2.0M | $3.3M | $2.3M |
| Operating income | −$68.8M | −$61.0M | −$92.7M | −$62.1M | −$40.4M |
| Net income | −$61.4M | −$52.8M | −$71.1M | −$58.2M | −$55.3M |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M |
| Equity | $5.6M | $25.6M | $66.9M | $127.3M | −$111.5M |
| EPS (diluted) | $-2.73 | $-12.03 | $-16.01 | $-2.23 | $-19.00 |
| Shares out. | 26.0M | 45.8M | 44.2M | 43.4M | 3.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −312631.8%
- Net margin
- −279263.6%
- Return on equity
- −1099.3%
- Return on assets
- −119.9%
- Return on capital (ROCE)
- −184.6%
- Liabilities / assets
- 89.1%
- Debt / equity
- 8.16×
- Book value / share
- $0.21
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -30.52distress
- Accruals / assets
- −35.1%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Celadon Partners Spv 24Activist (13D)May 4, 2026
- Bayer Healthcare LlcActivist (13D)Apr 16, 2026
- New Enterprise Associates 15, L.P.Activist (13D)Mar 31, 2026
- Armistice Capital, LlcPassive (13G)May 15, 2025
- Nantahala Capital Partners Limited PartnershipPassive (13G)May 15, 2025
- Nantahala Capital Management, LlcPassive (13G)May 15, 2025
- Lonsdale JoePassive (13G)May 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Rajangam KanyaOfficer — Pres. & Chief Med. & Dev. Off. | Mar 9, 2026 | Tax withholding | 10,757 | $0.00 |
| Lu Timothy KOfficer — CEO | Mar 9, 2026 | Tax withholding | 80,666 | $0.00 |
| Rajangam KanyaOfficer — Pres. & Chief Med. & Dev. Off. | Feb 2, 2026 | Tax withholding | 1,384 | $0.00 |
| Lu Timothy KOfficer — CEO | Feb 2, 2026 | Tax withholding | 4,191 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 648,528 | 3.1 | -2.7% |
| Apr 30, 2026 | 666,771 | 2.4 | +2.2% |
| Apr 15, 2026 | 652,268 | 6.8 | -11.4% |
| Mar 31, 2026 | 736,084 | 6.2 | -2.0% |
| Mar 13, 2026 | 751,516 | 6.4 | -7.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligationMay 26, 2026
- Results of operations · Other material eventMay 14, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Change in controlMay 1, 2026
- Other material eventApr 1, 2026
- Results of operationsMar 27, 2026
- Entered a material agreementMar 19, 2026
- Regulation FD disclosure · Other material eventDec 9, 2025
- Results of operationsNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (4)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.